BDX Shares Decline 2% Following Launch of AI-Enhanced Research Platform

Bristol-Myers Squibb (NYSE: BDX) shares fell 2% on Friday following the company's unveiling of an AI-powered research platform aimed at accelerating drug discovery. The new tool, named "AI Insights," integrates machine learning algorithms to analyze vast datasets, potentially reducing development timelines by up to 30%. Analysts noted that while the innovation could enhance long-term competitiveness, investors remain cautious amid rising regulatory scrutiny in biotech. The stock traded at $158.75 as of 20:30 UTC, down from its previous close of $162.00. BDX management emphasized the platform's role in addressing unmet medical needs, but some market observers questioned its immediate financial impact. The broader biotech sector also experienced a slight dip, with the Nasdaq Biotechnology Index declining 0.8% over the same period.